Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
2.050
+0.100 (5.13%)
At close: Nov 14, 2025, 4:00 PM EST
2.100
+0.050 (2.42%)
After-hours: Nov 14, 2025, 6:34 PM EST
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $182.34K in the twelve months ending September 30, 2025, down -10.36% year-over-year. In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%.
Revenue (ttm)
$182.34K
Revenue Growth
-10.36%
P/S Ratio
772.43
Revenue / Employee
$1,361
Employees
134
Market Cap
140.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INO News
- 3 days ago - Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress - Seeking Alpha
- 4 days ago - INOVIO Announces Pricing of $25 Million Public Offering - PRNewsWire
- 5 days ago - Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 5 days ago - INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 12 days ago - INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults - PRNewsWire
- 15 days ago - INOVIO Reports Inducement Grant Under Inducement Plan - PRNewsWire
- 19 days ago - INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025 - PRNewsWire